Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2017.6595

mmr-16-01-0238

Articles

Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy

Luo

Pei

1 * Yang

Qing

1 * Cong

Le-Le

2 * Wang

Xiao-Feng

3 * Li

Yu-Sheng

4 Zhong

Xiao-Ming

5 Xie

Ru-Ting

1 Jia

Cheng-You

6 Yang

Hui-Qiong

1 Li

Wen-Ping

1 Cong

Xian-Ling

7 Xia

Qing

3 Fu

6 Zeng

Qing-Hua

8 Ma

Yu-Shui

6 9

1College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, P.R. China 2Department of Neurology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130031, P.R. China 3Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China 4Department of Orthopedics, Xiangya Hospital, Central-South University, Changsha, Hunan 410008, P.R. China 5Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029, P.R. China 6Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China 7Tissue Bank, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China 8Department of Respiratory, The First Affiliated Hospital of Nanchang University, Nanchang 330006, P.R. China 9Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China

Correspondence to: Dr Yu-Shui Ma, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai 200072, P.R. China, E-mail: mayushui2015@126.com Dr Qing-Hua Zeng, Department of Respiratory, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Road, Nanchang 330006, P.R. China, E-mail: s13979160266@qq.com *

Contributed equally

072017

17052017

16 1 238 246 04022016 20022017

2017

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Previous studies have suggested that dysregulation of microRNA (miR) −124a is associated with various types of human cancer. However, there are few studies reporting the level of miR-124a expression in non-small cell lung cancer (NSCLC). The present study investigated the association between miR-124a and NSCLC by analyzing the differential expression of miR-124a in NSCLC using the GEO database, as well as subsequently performing reverse transcription-quantitative polymerase chain reaction analysis on 160 NSCLC biopsies, 32 of which were paired with adjacent normal tissues. The results indicated that mir-124a expression levels were decreased in NSCLC tumor biopsies compared with adjacent normal tissues. The overall survival (OS) in patients with a high expression of miR-124a was prolonged relative to patients with low expression of miR-124a. The expression levels of miR-124a were associated with clinical characteristics, including lymph-node metastasis, tumor differentiation, tumor node metastasis (TNM) stage and diameter. Frequently, lymph-node metastasis, TNM stage, diameter and lack of chemotherapy have been associated with a worse prognosis in patients. In addition, the present study identified that high expression of miR-124awith chemotherapy may increase OS. In conclusion, the current study demonstrated that miR-124a was downregulated in NSCLC, and miR-124a was a potential prognostic tumor biomarker response to chemotherapy.

microRNA-124 non-small cell lung cancer chemotherapy overall survival disease-free survival biomarker prognosis

Introduction

Lung cancer is one of the most common malignancies and is the major cause of cancer-associated mortality, accounting for ~1.38 million deaths each year (1,2). Of all lung carcinomas, non-small cell lung cancer (NSCLC) accounts for ~70–85% (3). Although there have been recent advances in diagnosis and treatment, the prognosis of lung cancer is still unfavorable and the 5-year overall survival (OS) rate remains <15% (4,5). In previous decades, studies reported that microRNAs (miRNAs/miRs) may serve an important role in NSCLC pathogenesis, which provides novel insights into disease biology (6,7). Therefore, improved understanding of detailed mechanisms of NSCLC with miRNAs is necessary for development of effective therapeutic strategies.

miRNAs are a class of 20–24 nucleotide-long non-coding RNAs, which regulate gene expression at the post-transcriptional level through mRNA interference, and are involved in cell development, proliferation, differentiation and apoptosis (8,9). There are currently ~2000 miRNAs that have been identified and this number is rapidly increasing. A large number of miRNAs have been investigated in cancer research as therapeutic targets, with certain miRNAs identified as being associated with the tumor metastasis of NSCLC. For instance, upregulation of miR-24 promotes cell proliferation by targeting nuclear apoptosis inducing factor 1in NSCLC (10). Overexpression of miR-328 has a role in conferring migratory potential to NSCLC cells through targeting protein kinase C alpha (11). miR-34c-3p functions as a tumor suppressor by inhibiting eukaryotic initiation factor-4E expression in NSCLC (12). miR-99a suppresses the metastasis of human NSCLC by targeting AKT serine/threonine kinase 1 (13). However, there are few studies researching the expression of miR-124a in NSCLC and the detailed molecular mechanism of miR-124a in NSCLC requires further investigation.

In the present study, the differential expression of miR-124a in NSCLC was analyzed using the GEO database and the association between miR-124a and NSCLC was subsequently revealed. Furthermore, the expression status of miR-124a in NSCLC was identified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for a group of NSCLC biopsies. Furthermore, the prognostic significance of NSCLC and the response to chemotherapy was assessed.

Materials and methods <sec> <title>Data and date source

All miR-124a expression datasets were downloaded from GEO (www.pubmed.com/geo). Data were retrieved using the keywords ‘miR-124a’ and ‘NSCLC’. The first data set, GSE10021, has samples taken from 16 human cell lines (14), and includes the following cell lines: Human lung carcinoma A549, fibrosarcoma HT1080, cervix carcinoma Henrietta Lacks, cervix carcinoma HeLaS3, hepatocellular carcinoma Huh7, breast adenocarcinoma MCF7, breast adenocarcinoma MDAMB231, embryonal kidney HEK293T, colon adenocarcinoma HT29, hepatocellular carcinoma HepG2, neuroblastoma SKNMC, colon adenocarcinoma Caco2, embryonal kidney HEK293 and colon carcinoma HCT116. The second data set, GSE61741, has samples taken from normal patients and patients with cancer (15), and it has a total of 1,049 samples out of which 94 were normal and 15 were long-lived individuals and 940 patients had been screened for the complete miRNA repertoire. The third data set, GSE63805, has samples taken from normal patients and patients with lung cancer (16), and it has a total of 62 samples out of which 31 were normal and 31 were cancerous. The last data set, GSE17681, has samples taken from normal patients and patients with lung cancer (17), and it has a total of 36 samples out of which 19 were normal and 17 were cancerous.

Clinical specimens

A total of 160 cases of surgically resected NSCLC and 32 paired normal adjacent lung tissue samples were evaluated for miRNA expression. These specimens were collected from patients from the tissue bank in China-Japan Union Hospital, Jilin University (Changchun, China) between January 2008 and December 2012. All patients gave their informed consent, and the Ethical and Scientific Committees of Shanghai Tenth People's Hospital, Tongji University School of Medicine (Shanghai, China) approved the study. The tumors of NSCLC were staged based on the 7th edition of the AJCC tumor node metastasis (TNM) staging system (18). In addition, several clinical characteristics of these patients were assessed, including age, gender, lymph-node metastasis, tumor differentiation, histological subtypes, TNM stage, invasion of lung membrane, vascular invasion, tumor size, chemotherapy, miR-124a expression status, OS and disease-free survival (DFS). Age was stratified according to ≥60 or <60 years. Tumor size was divided into ≥5 and <5 cm based on the mean tumor diameter. OS represented the date of diagnosis to the date of death, from any cause. DFS was represented the original date of diagnosis to the first date of recurrence, or death. All clinical data were confirmed by the patient or relatives, by medical recording, by the social security record, or by follow-up record.

RNA extraction and RT-qPCR

Total RNA was extracted from tissues using the TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's instructions. RNA concentration and purity was assessed using a NanoDrop ND-1000 (Thermo Fisher Scientific, Inc.). A total of10 ng total RNA was used for cDNA synthesis using the Taqman MicroRNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Reverse transcription with a miR-124a-specific primer was performed using ABI's TaqMan MicroRNA Reverse Transcription kit, miR-124a expression level was detected using a Taqman MicroRNA assay (Applied Biosystems; Thermo Fisher Scientific, Inc.) (19). The RT-qPCR thermocycling conditions were as follows: 94°C for 30 sec (initial denaturation), 94°C for 5 sec (denaturation) and 55°C for 30 sec (annealing), for 40 cycles. U6 expression was used as the internal control. The following primers were used: miR-124a forward, 5′-GGTAAGGCACGCGGT-3′, and reverse, 5′-CAGTGCGTGTCGTGGAGT-3′; U6 forward, 5′-CTGGTTAGTACTTGGACGGGAGAC-3′, and reverse, 5′-GTGCAGGGTCCGAGGT-3′. All reactions were performed three times in triplicate, and relative expression of miRNAs was calculated using the standard curve and the ΔΔCq method (20).

Statistical analysis

All statistical data were analyzed using SPSS software (version, 19.0; IBM SPSS; Armonk, NY, USA). Significant differences between the two groups were evaluated using an independent t-test. The expression of miR-124a and other data were presented as the mean ± standard deviation. χ² test analysis was used to assess differences in patient characteristics. OS rates were calculated actuarially according to the Kaplan-Meier method and results were compared with a log-rank test. To examine which individual characteristics played important roles in survival, univariate and multivariate Cox regression analysis were conducted. P<0.05 was considered to indicate a statistically significant difference and P<0.001 was considered highly significant.

Results <sec> <title>Analysis of miR-124a expression using an online database

The expression of miR-124a in 16 different cell lines was analyzed via the GEO database (Fig. 1A), which revealed that miR-124a exhibited relatively decreased expression in lung cancer A549 cells, when compared with most other cell lines.

miR-124a was identified as being relatively expressed in 104 normal samples (114.41±64.55), 120 Wilms' tumor samples (102.75±60.35), 14 gastric cancer samples (98.68±48.73), 62 lung cancer samples (89.27±45.46), 19 glioma samples (81.19±49.43), 33 melanoma samples (79.69±49.62), 20 renal cancer samples (76.57±45.03) and 27 colon cancer samples (72.06±37.34), using the GEO database (Fig. 1B). The results indicated that miR-124a exhibited decreased expression in tumor tissues, when compared with normal tissue.

A total of 30 paired lung cancer tissues were investigated from a dataset on the GEO database (Fig. 1C). The fold-change for relative miR-124a expression levels was calculated using the Log2 ratio of paired tumor/normal expression, and miR-124awas observed to be downregulated in over half of the lung cancer cases [fold change (FC) =0.81; P=0.021].

Relative miR-124a expression in 17 lung cancer blood samples vs. 17 adjacent normal tissues was investigated using the GEO database (Fig. 1D). The analysis suggested that miR-124a was downregulated in lung cancer tissues (18.55±6.75), when compared with adjacent normal tissues (40.76±16.48; FC=0.45; P=0.048).

miR-124a expression in NSCLC and normal lung tissue

To validate these findings, 32 paired lung cancer tissues were evaluated using RT-qPCR (Fig. 2A). The results demonstrated that miR-124a was expressed at significantly decreased levels in most lung cancer cases (FC=0.64; P=0.032). In addition, the expression levels of miR-124a were examined in tumor (n=160) and adjacent non-neoplastic tissues (n=32) using RT-qPCR (Fig. 2B), which demonstrated that miR-124a expression levels were significantly decreased in NSCLC tumor biopsies (1.14±0.85), when compared with adjacent normal tissues (1.76±0.63; FC=0.65; P=0.034).

Association between miR-124a expression and clinical characteristics

Univariate analysis was used to investigate the relationship between miR-124a expression and clinical characteristics in 160 cases of NSCLC. The results revealed that the expression levels of miR-124a were significantly associated with lymph node metastasis (P=0.021), tumor differentiation (P=0.047), TNM stage (P=0.036) and diameter (P=0.026; Table I). Conversely, the results demonstrated that age, gender, smoking history, histology, invasion of lung membrane, vascular invasion and chemotherapy have no significant association with miR-124a expression (P>0.05; Table I).

Expression levels of miR-124a area prognostic marker in NSCLC survival

Univariate analysis of OS based on patients stratified by clinical characteristics presented in Table I. These clinical characteristics with univariate analysis included age, gender, smoking history, lymph-node metastasis, tumor differentiation, histology, TNM stage, invasion of lung membrane, vascular invasion, tumor diameter and miR-125a-3p expression. Obviously, there was a meaningful relationship between short OS and several clinical characteristics, including lymph-node metastasis (P=0.039), TNM stage (P=0.027), diameter (P<0.001) and lack of treatment with chemotherapy (P=0.029). Conclusively, it was identified that the patients who exhibited lymph-node metastasis, high TNM stage, tumor size exceeding 0.5 cm or those who had not received chemotherapy exhibited increased mortality (decreased OS).

To determine which clinical characteristics were associated with the prognosis of NSCLC, univariate survival analysis with Kaplan-Meier were performed. Several clinical parameters with Kaplan-Meier survival curves presented a good prognosis for patients with NSCLC. Negative lymph-node metastasis was significantly associated with increased OS (P=0.039; Fig. 3A) and DFS (P=0.018; Fig. 3B) in patients with NSCLC. Similarly, low TNM stage was positively associated with increased OS (P=0.027; Fig. 3A) and DFS (P=0.025; Fig. 3B). In addition, tumor size was significantly associated with increased OS (P<0.001; Fig. 3E) and DFS (P=0.009; Fig. 3F).

Univariate analysis with a Cox proportional hazards regression model was used to explore the prognosis of clinical characteristics. The result revealed that there were four parameters significantly associated with good prognosis, including lymph node metastasis [P=0.03; HR=1.72 (1.18–2.96); Table II], TNM stage [P=0.02; HR=1.83 (1.56–2.64); Table II], tumor diameter [P<0.001; HR=2.56 (2.07–5.46); Table II], as well as miR-124a expression [P=0.023; HR=0.68 (0.52–0.73); Table II]. There was no association between prognosis and several parameters, including age, gender, smoking history, tumor differentiation, histology, invasion of lung membrane or vascular invasion. Therefore, these results suggested that miR-124a serves an important role in NSCLC progression. In addition, it was summarized that miR-124a is involved in the prognosis of NSCLC patients.

To further investigate the association between miR-124a expression and the prognosis of patients with NSCLC, multivariate Cox proportional hazards regression analysis was conducted. The model included all of the characteristics relative to predicted OS in the univariate analysis of the entire patients as presented in Table I. There were three characteristics that presented a significant association with prognosis, including lymph-node metastasis [P=0.015; HR=1.98 (1.25–3.03); Table II], TNM stage [P=0.009; HR=2.13 (1.61–2.89); Table II] and tumor diameter [P<0.001; HR=3.65 (2.26–5.43); Table II]. Multivariable Cox regression model analysis revealed that increased expression of miR-124a was determined to be a predictor of increased OS in patients with NSCLC.

Association amongst survival, chemotherapy and miR-124a expression

Chemotherapy is a major treatment of NSCLC, thus it was analyzed as an influential factor inOS and DFS. According to Table III, chemotherapy was demonstrated to significantly prolong OS (29.94±1.57 vs. 22.58±1.96; P=0.029) and DFS (26.43±3.56 vs. 20.06±3.78; P=0.032) in the entire group. By comprehensive analysis of chemotherapy and miR-124a expression level, it was concluded that patients who received chemotherapy with high expression of miR-124a exhibited an increased OS (32.78±6.96 vs. 20.43±3.58; P=0.001) and DFS (29.33±2.65 vs. 20.06±3.98, P<0.001), compared with those who did not receive chemotherapy with low expression of miR-124a.

To further identify whether chemotherapy or with miR-124a expression was associated with OS and DFS, univariate and multivariate survival analysis with Kaplan-Meier estimates were conducted. The result of univariate survival analysis indicated that increased OS (P=0.029; Fig. 4A) and DFS (P=0.032; Fig. 4B) was significantly associated with chemotherapy compared with the results from untreated patients. In addition, high expression of miR-124a increased OS (P=0.023; Fig. 4C) and DFS (P=0.015; Fig. 4D) when compared with low expression. The result of multivariate survival analysis demonstrated that chemotherapy with high expression of miR-124a prolonged OS (P<0.001; Fig. 4E) and DFS (P<0.001; Fig. 4F).

Discussion

Evidence has demonstrated that miRNAs regulated cell proliferation, cell metastasis and apoptosis at a post transcriptional level. There are previous studies that have reported that miRNAs serve a crucial role in the development of chemosensitivity or chemoresistance in NSCLC (21,22). In addition, miRNAs expression level has been identified to be associatedwith tumor development (23). In recent years, miRNAs have been used to detect early diagnosis, prognosis and therapeutic evaluation (24).

miR-124a has been identified to be a novel suppressor for cancer, and has been reported to be associated with the suppressive effects of a variety of human cancers, including breast, glioma, gastric cancer and colitis (25). Certain previous studies reported that methylation of miR-124a is associated with aggressive and advanced breast cancer disease (26,27). Furthermore, miR-124a has been investigated to potentially inhibit glioma cell proliferation and invasion by blocking the expression of a particular gene (28,29). In addition, the methylation of miR-124a was identified early in colorectal carcinogenesis (30,31) and was epigenetically silenced in the development of uveal melanoma (32).

In the present study, the expression of miR-124a in 160 NSCLC tissues and 32 paired normal tissues was evaluated. Several previous papers reported that miR-124a expression level in normal tissues is higher than those in lung cancer tissues (33–35). Consistently, miR-124a expression levels were lower in NSCLC tumor biopsies, when compared to adjacent normal tissues. The OS in patients with high expression of miR-124a was prolonged relative to patients with low expression of miR-124a. Therefore, miR-124a may bea deregulated gene in NSCLC. The expression levels of miR-124a were associated with clinical characteristics, including lymph-node metastasis, tumor differentiation, TNM stage and diameter. Frequently, lymph-node metastasis, TNM stage, diameter and chemotherapy are associated with a worse prognosis in patients. Therefore, there was a significant association between miR-124a and prognosis. In addition, there was a high expression of miR-124a identified with chemotherapy that may increase OS. Therefore, it was concluded that miR-124a may act as a biomarker for response to chemotherapy in NSCLC.

Furthermore, the authors explored the biomarker role of miR-124a in NSCLC. To the best of the authors' knowledge, it is the first attempt to identify the status of miR-124a for chemotherapy in NSCLC. Generally, tumor metastasis is a major cause of high mortality of NSCLC. In recent decades, chemotherapy has remained as the central therapeutic mainstay in metastatic lung cancer, despite response rates being maintained at 30–40% and the median survival being 7–12 months (36). For the past few years, characteristic molecules began to play an important role in cancer treatment (37). It is reported that molecular biomarkers successfully respond to NSCLC chemotherapy as diagnostic biomarkers and prognostic factors. For instance, Perez-Carbonell et al (38) demonstrated that miR-320e was a novel prognostic biomarker associated with adverse clinical outcome in patients with stage III colorectal cancer treated with 5-FU-based adjuvant chemotherapy. In addition, miR-22, miR-24, miR-34a and miR-638 were investigated as novel predictive biomarkers (39,40). Furthermore, miR-200c, miR-744 and miR-34a, have been reported to be prognostic biomarkers in esophageal cancer, pancreatic cancer and breast cancer (41–43).

In conclusion, the present study reported the clinical and prognostic relevance of miR-124a in patients with NSCLC. These data revealed that the OS and DFS of patients undergoing chemotherapy were prolonged in comparison with those not receiving chemotherapy. Furthermore, patients who exhibited increased expression of miR-124a with chemotherapeutic treatment presented the longest OS and DFS, compared with those who exhibited decreased expression of miR-124a without chemotherapy. Conclusively, miR-124a is a predictive biomarker for the prognosis of NSCLC with chemotherapy. In future studies, bioinformatic and transcriptomic approaches, as well as functional analysis, will be necessary to investigate the mechanistic role of miR-124a in NSCLC and to confirm the present results.

Acknowledgements

The present study was partially supported by grants from the National Natural Science Foundation of China (grant nos. 81201535, 81472202 and 81302065), Shanghai Natural Science Foundation (grant nos. 12ZR1436000 and 16ZR1428900) and Shanghai Municipal Commission of Health and Family Planning (grant nos. 201440398 and 201540228), Jiangxi Province Department of Science Plan Funded Projects (grant no. 2011BBG70046), Hunan Natural Science Fund for Distinguished Young Scholars Project (grant no. 2015JJ1009) and the Jilin Provincial Science and Technology Department (grant nos. 20130727029YY, 20140f14061GH and 20150204057SF).

References 1

Hamamoto

Soejima

Yoda

Naoki

Nakayama

Satomi

Terai

Ikemura

Sato

Yasuda

Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma

Mol Med Rep84564622013

23759980

Meng

Cui

Perry

Dedousi-Huebner

Huebner

Wang

Volinia

Nakanishi

MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma

Clin Cancer Res19542354332013

10.1158/1078-0432.CCR-13-0320

23946296

Tiseo

Bordi

Bortesi

Boni

Baldini

Grossi

Recchia

Zanelli

Fontanini

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

Br J Cancer108169517032013

10.1038/bjc.2013.127

23549037

3669730

Markou

Sourvinou

Vorkas

Yousef

Lianidou

Clinical evaluation of microRNA expression profiling in non small cell lung cancer

Lung Cancer813883962013

10.1016/j.lungcan.2013.05.007

23756108

Mitra

Edmonds

Sun

Zhao

Eischen

Zhao

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer

RNA20135613682014

10.1261/rna.042754.113

25024357

4138319

Xie

Zhu

Zhang

MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2

Tumour Biol37119712042016

10.1007/s13277-015-3831-2

26282001

Zhou

Qiao

MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway

Int J Clin Exp Pathol8631263222015

26261507

4525841

Agirre

Vilas-Zornoza

Jiménez-Velasco

Martin-Subero

Cordeu

Gárate

San

José-Eneriz E

Abizanda

Rodríguez-Otero

Fortes

Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

Cancer Res69444344532009

10.1158/0008-5472.CAN-08-4025

19435910

Pierson

Hostager

Fan

Vibhakar

Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma

J Neurooncol90172008

10.1007/s11060-008-9624-3

18607543

Zhao

Liu

Zhao

Jin

Jiang

Cao

Han

Xin

Dong

Liu

Cui

Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer

Tumour Biol36369337012015

10.1007/s13277-014-3008-4

25725584

Arora

Ranade

Tran

Nasser

Sridhar

Korn

Ross

Dhruv

Foss

Sibenaller

MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration

Int J Cancer129262126312011

10.1002/ijc.25939

21448905

3154499

Liu

Wang

Zhang

Che

Cao

Jin

miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer

Cell Prolif485825922015

10.1111/cpr.12201

26250586

Zhang

Dong

Zhang

miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway

J Cell Biochem1162682762015

10.1002/jcb.24965

25187230

Ruike

Ichimura

Tsuchiya

Shimizu

Kunimoto

Okuno

Tsujimoto

Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines

J Hum Genet535155232008

10.1007/s10038-008-0279-x

18465083

Keller

Leidinger

Vogel

Backes

ElSharawy

Galata

Mueller

Marquart

Schrauder

Strick

miRNAs can be generally associated with human pathologies as exemplified for miR-144

BMC Med122242014

10.1186/s12916-014-0224-0

25465851

4268797

Robles

Arai

Mathé

Okayama

Schetter

Brown

Petersen

Bowman

Noro

Welsh

An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers

J Thorac Oncol10103710482015

10.1097/JTO.0000000000000560

26134223

4493931

Keller

Leidinger

Borries

Wendschlag

Wucherpfennig

Scheffler

Huwer

Lenhof

Meese

miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments

BMC Cancer93532009

10.1186/1471-2407-9-353

19807914

2764731

Edge

Compton

The American Joint Committee on Cancer: The 7^th edition of the AJCC cancer staging manual and the future of TNM

Ann Surg Oncol17147114742010

10.1245/s10434-010-0985-4

20180029

Chen

Ridzon

Broomer

Zhou

Lee

Nguyen

Barbisin

Mahuvakar

Andersen

Real-time quantification of microRNAs by stem-loop RT-PCR

Nucleic Acids Res33e1792005

10.1093/nar/gni178

16314309

1292995

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Acunzo

Visone

Romano

Veronese

Lovat

Palmieri

Bottoni

Garofalo

Gasparini

Condorelli

miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222

Oncogene316346422012

21706050

Garofalo

Romano

Di Leva

Nuovo

Jeon

Ngankeu

Sun

Lovat

Alder

Condorelli

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

Nat Med1874822011

22157681

3467100

Hou

Han

Luo

Chang

Xie

Yang

Chai

Cai

Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy

PLoS One12e01704312017

10.1371/journal.pone.0170431

28141816

5283662

Faversani

Amatori

Augello

Colombo

Porretti

Fanelli

Ferrero

Palleschi

Pelicci

Belloni

miR-494-3p is a novel tumor driver of lung carcinogenesis

Oncotarget8723172472017

27980227

Zhou

Long

Zhou

Tian

Zhou

Demethylation of MicroRNA-124a genes attenuated proliferation of rheumatoid arthritis derived fibroblast-like synoviocytes and synthesis of tumor necrosis factor-α

PLoS One11e01642072016

10.1371/journal.pone.0164207

27824863

5100945

Ben Gacem

Ben

Abdelkrim O

Ziadi

Ben Dhiab

Trimeche

Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease

Tumour Biol35404740562014

10.1007/s13277-013-1530-4

24375250

Liang

Wang

Zhou

Yin

Cao

Chen

Zhao

MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer

Carcinogenesis347137222013

10.1093/carcin/bgs383

23250910

Tivnan

Zhao

Johns

Day

Stringer

Boyd

Tiwari

Giles

Teo

McDonald

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma

Tumour Biol35145914652014

10.1007/s13277-013-1200-6

24068568

Jiang

Xiao

Liu

Yuan

miR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and β-catenin

Oncol Rep32210421102014

25175832

Deng

Kakar

Kim

MicroRNA-124a and microRNA-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa

Oncol Lett21751802011

22870149

Ueda

Ando

Nanjo

Ushijima

Sugiyama

DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis

Dig Dis Sci59244424512014

10.1007/s10620-014-3193-4

24825593

Chen

Dong

Wang

Tang

Yan

MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma

Invest Ophthalmol Vis Sci54224822562013

10.1167/iovs.12-10977

23404119

Feng

Chen

Wang

Identification of host encoded microRNAs interacting with novel swine-origin influenza A (H1N1) virus and swine influenza virus

Bioinformation41121182009

10.6026/97320630004112

20198183

2828889

Kim

Lee

Son

Kim

Park

Combined effect of metastasis-related MicroRNA, miR-34 and miR-124 family, methylation on prognosis of non-small-cell lung cancer

Clin Lung Cancer18e13e202017

10.1016/j.cllc.2016.06.005

27444357

Liu

Gao

Hou

Yao

Cui

The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients

Int J Oncol467988082015

25531908

Paz-Ares

de Marinis

Dediu

Thomas

Pujol

Bidoli

Molinier

Sahoo

Laack

Reck

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial

Lancet Oncol132472552012

10.1016/S1470-2045(12)70063-3

22341744

Lee

Jung

Kim

Rhee

Park

Kim

Lee

Chung

Whole-exome sequencing identified mutational profiles of high-grade colon adenomas

Oncotarget8657965882017

28179590

Perez-Carbonell

Sinicrope

Alberts

Oberg

Balaguer

Castells

Boland

Goel

MiR-320e is a novel prognostic biomarker in colorectal cancer

Br J Cancer11383902015

10.1038/bjc.2015.168

26035698

4647533

Franchina

Amodeo

Bronte

Savio

Ricciardi

Picciotto

Russo

Giordano

Adamo

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer

J Cell Physiol22997992014

23794259

Wang

Lou

Cao

Shi

Wang

Xie

Sun

Rao

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy

Exp Mol Med47e1622015

10.1038/emm.2015.17

25952770

4454993

Tanaka

Miyata

Yamasaki

Sugimura

Takahashi

Kurokawa

Nakajima

Takiguchi

Mori

Doki

Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer

Ann Surg Oncol20(Suppl 3)S607S6152013

10.1245/s10434-013-3093-4

23838916

Miyamae

Komatsu

Ichikawa

Kawaguchi

Hirajima

Okajima

Ohashi

Imamura

Konishi

Shiozaki

Plasma microRNA profiles: Identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer

Br J Cancer113146714762015

10.1038/bjc.2015.366

26505678

4815891

Frères

Josse

Bovy

Boukerroucha

Struman

Bours

Jerusalem

Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression

J Cell Physiol2304734812015

10.1002/jcp.24730

25078559

Figure 1.

Analysis of miR-124a expression in NSCLC patients using the GEO database. (A) Expression levels of miR-124a in 16 different cell lines derived from the GEO database. (B) Expression levels of miR-124ain normal vs. other cancers derived from the GEO database. (C) Expression levels of miR-124ain 30 paired lung cancer tissues derived from the GEO database. The fold-change for miR-124a expression levels was calculated using thelog2 ratio of paired tumor/normal expression. (D) Expression levels of miR-124ain normal vs. 17 paired lung cancer tissues derived from the GEO database. *P<0.05, **P<0.01 vs. normal tissues. miR, microRNA; NSCLC, non-small cell lung cancer; GEO, Gene Expression Omnibus; FC, fold change.

Figure 2.

Analysis of miR-124a expression in 32 paired NSCLC tissues using the reverse transcription-quantitative polymerase chain reaction. (A) Expression levels of miR-125a-3p in 32 paired NSCLC tissues. (B) Expression levels of miR-125a-3p in 32 normal vs. 160 lung cancer tissues. NSCLC, non-small cell lung cancer; miR, microRNA; FC, fold change.

Figure 3.

Univariate survival analysis of different clinical parameters in non-small cell lung cancer. Univariate survival analysis of (A) overall survivaland (B) disease-free survival stratified by lymph node metastasis, (C) overall survival and (D) disease-free survival stratified by tumor node metastasis stage, and (E) overall survival and (F) disease-free survival stratified by tumor diameter, as determined by Kaplan-Meier plots estimates.

Figure 4.

Survival analysis of chemotherapy and miR-124a expression in non-small cell lung cancer. Univariate survival analysis of (A) overall survival and (B) disease-free survival stratified by chemotherapy, (C) overall survival and (D) disease-free survival stratified by miR124-a expression, and (E) overall survival and (F) disease-free survival stratified by chemotherapy and miR-124a expression, as determined by Kaplan-Meier plots estimates. miR, microRNA; P&H, chemotherapy and high miR-124a expression; N&L, no chemotherapy and low miR-124a expression.

Table I.

Univariate analysis of overall patient survival stratified by clinical characteristics.

					Overall survival

Characteristic	Variable	n	miR-124a expression, mean ± standard deviation	P-value	Months, mean	95% CI, mean	P-value (log-rank test)
Age
	≥60 years	97	1.26±0.63	0.281	22.34	21.06–23.17	0.326
	<60 years	63	1.11±0.62		25.19	22.45–29.63
Gender
	Male	97	1.19±0.61	0.487	24.76	22.09–26.04	0.168
	Female	63	1.21±0.66		25.33	21.58–28.33
Smoking history
	Never	38	1.29±0.42	0.115	26.11	24.39–28.63	0.091
	Ever	65	1.18±0.79		24.86	22.77–26.34
	Unknown	57	1.26±0.67		26.34	24.91–28.76
Lymphnode metastasis				0.021			0.039
	Negative	91	1.39±0.81		26.38	24.73–33.59
	Positive	57	1.11±0.13		20.44	17.06–24.31
	Unknown	12	1.18±0.96		22.56	20.84–25.69
Tumor differentiation				0.047			0.225
	Poor	18	0.86±0.25		24.03	24.60–33.68
	Moderate	84	1.18±0.13		26.68	22.28–28.34
	Well	58	1.39±0.26		26.56	22.70–29.75
Histology
	Adenocarcinoma	55	1.19±0.53	0.634	26.63	23.47–29.86	0.353
	Squamous cell carcinoma	105	1.27±0.38		25.98	23.33–28.74
TNM stage
	I–II	104	1.28±0.38	0.036	27.58	24.19–30.36	0.027
	III–IV	56	0.81±0.26		23.46	18.69–25.43
Invasion of lung membrane				0.068			0.088
	Negative	34	1.24±0.68		30.36	22.68–41.33
	Positive	114	0.99±0.86		26.83	22.48–28.55
	Unknown	12	1.18±0.37		25.43	22.68–26.47
Vascular invasion
	Negative	145	1.21±0.79	0.691	26.58	21.67–29.23	0.318
	Positive	3	0.97±0.83		25.24	23.36–42.58
	Unknown	12	1.21±0.36		24.37	21.48–30.59
Chemotherapy
	Negative	80	1.17±0.36	0.543	20.58	18.69–24.37	0.029
	Positive	69	1.25±0.63		26.94	23.06–28.94
	Unknown	11
Diameter
	≥5 cm	39	0.88±0.35	0.026	21.93	18.45–26.04	<0.001
	<5 cm	121	1.36±0.62		27.86	25.39–29.28

miR-124a, microRNA-124a; CI, confidence interval; TNM, tumor node metastasis.

Table II.

Cox regression model analysis for prognosis based on various clinical characteristics of patients with non-small cell lung cancer.

				miR-124a multivariate analysis

Factor	HR	95% CI (univariate)	P-value	HR	95% CI (multivariate)	P-value
Age	0.96	0.69–1.14	0.45
Gender	0.87	0.53–1.16	0.18
Smoking history	1.21	0.71–1.52	0.19
Lymph-node metastasis	1.72	1.18–2.96	0.03	1.98	1.25–3.03	0.015
Tumor differentiation	0.88	0.54–1.01	0.18
Histology	1.18	0.86–1.21	0.34
TNM stage	1.83	1.56–2.64	0.02	2.13	1.61–2.89	0.009
Invasion of lung membrane	1.22	1.06–1.37	0.15
Vascular invasion	0.98	0.68–1.54	0.31
Diameter	2.56	2.07–5.46	<0.001	3.65	2.26–5.43	<0.001
miR-124a expression	0.68	0.52–0.73	0.023

HR, hazard ratio; miR-124a, microRNA-124a; CI, confidence interval; TNM, tumor node metastasis.

Table III.

OS and DFS of patients with non-small cell lung cancer stratified by chemotherapy alone, or chemotherapy and miR-124a expression.

	OS			DFS

	Mean ± SD	95% CI	P-value	Mean ± SD	95% CI	P-value
Chemotherapy
Positive	29.94±1.57	23.06–33.94	0.029	26.43±3.56	25.43–28.04	0.032
Negative	22.58±1.96	18.69–24.37		20.06±3.78	18.78–25.33
Chemotherapy+expression
P+H	32.78±6.96	26.79–36.43	0.001	29.33±2.65	26.04–33.41	<0.001
N+L	20.43±3.58	16.98–22.54		20.06±3.98	18.07–24.49

OS, overall survival; DFS, disease-free survival; SD, standard deviation; CI, confidence interval; P+H, chemotherapy and high miR-124a expression; N+L, no chemotherapy and low miR-124a expression.